About Genesis HealthCare (NYSE:GEN)

Genesis Healthcare, Inc. is a holding company that provides post-acute care. The Company operates through three segments: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services. As of December 31, 2016, the Company offered inpatient services through its network of 499 skilled nursing and assisted/senior living facilities across 34 states, consisting of 473 skilled nursing facilities and 26 stand-alone assisted/senior living facilities. Its services focus primarily on the medical and physical issues facing elderly patients and are provided by its skilled nursing companies, assisted or senior living communities, integrated and third-party rehabilitation therapy business, and other ancillary services.
Industry, Sector and Symbol
Industry Skilled nursing care facilities
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GEN
CUSIPN/A
Phone610-444-6350
Debt
Debt-to-Equity Ratio-2.98%
Current Ratio1.05%
Quick Ratio1.05%
Price-To-Earnings
Trailing P/E Ratio-0.75
Forward P/E Ratio-1.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.37 billion
Price / Sales0.05
Cash Flow$2.7069 per share
Price / Cash0.58
Book Value($10.74) per share
Price / Book-0.15
Profitability
EPS (Most Recent Fiscal Year)($2.11)
Net Income$-578,980,000.00
Net Margins-10.77%
Return on EquityN/A
Return on Assets-2.76%
Miscellaneous
Employees68,700
Outstanding Shares156,400,000
Genesis HealthCare (NYSE:GEN) Frequently Asked Questions
What is Genesis HealthCare's stock symbol?
Genesis HealthCare trades on the New York Stock Exchange (NYSE) under the ticker symbol "GEN."
How were Genesis HealthCare's earnings last quarter?
Genesis HealthCare (NYSE:GEN) released its earnings results on Friday, March, 16th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05. The business had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.34 billion. View Genesis HealthCare's Earnings History.
What price target have analysts set for GEN?
3 analysts have issued 12 month target prices for Genesis HealthCare's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Genesis HealthCare's stock price to reach $2.00 in the next twelve months. View Analyst Ratings for Genesis HealthCare.
Who are some of Genesis HealthCare's key competitors?
Some companies that are related to Genesis HealthCare include ObsEva (OBSV), Isotechnika Pharma (AUPH), ProMetic Life Sciences (PFSCF), Zealand Pharma (ZEAL), Innate Pharma (IPHYF), Vericel (VCEL), PDL Biopharma (PDLI), Concert Pharmaceuticals (CNCE), Depomed (DEPO), Zeltia (PHMMF), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Syros Pharmaceuticals (SYRS), Accuray (ARAY), Computer Programs and Systems (CPSI), Sinovac Biotech (SVA), Paratek Pharmaceuticals (PRTK) and Cara Therapeutics (CARA).
Who are Genesis HealthCare's key executives?
Genesis HealthCare's management team includes the folowing people:
- Robert H. Fish, Chairman of the Board
- George V. Hager Jr., Chief Executive Officer, Director
- Thomas DiVittorio, Chief Financial Officer
- Paul David Bach, Chief Operating Officer
- Jeanne Phillips, Chief Human Resource Officer, Senior Vice President
- , Bio & Compensation -
- David C. Almquist, Executive Vice President, President - West and East Divisions
- Richard P. Blinn, Executive Vice President, President - Northeast Division and Southeast Divisions
- JoAnne Reifsnyder Ph.D., Executive Vice President - Clinical Operations, Chief Nursing Officer
- Richard L. Castor, Senior Vice President, Chief Information Officer
- Michael S. Sherman, Senior Vice President, General Counsel, Assistant Treasurer, Secretary
Has Genesis HealthCare been receiving favorable news coverage?
News articles about GEN stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Genesis HealthCare earned a daily sentiment score of 0.04 on Accern's scale. They also gave headlines about the company an impact score of 46.33 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Genesis HealthCare's major shareholders?
Genesis HealthCare's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
FISHMAN STEVEN E.
(57.10%). Company insiders that own Genesis HealthCare stock include Daniel Allen Hirschfeld, George V Hager Jr, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View Institutional Ownership Trends for Genesis HealthCare.
How do I buy shares of Genesis HealthCare?
Shares of GEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genesis HealthCare's stock price today?
One share of GEN stock can currently be purchased for approximately $1.57.
How big of a company is Genesis HealthCare?
Genesis HealthCare has a market capitalization of $242.43 million and generates $5.37 billion in revenue each year. The company earns $-578,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Genesis HealthCare employs 68,700 workers across the globe.
How can I contact Genesis HealthCare?
Genesis HealthCare's mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company can be reached via phone at 610-444-6350 or via email at [email protected]
MarketBeat Community Rating for Genesis HealthCare (GEN)
MarketBeat's community ratings are surveys of what our community members think about Genesis HealthCare and other stocks. Vote "Outperform" if you believe GEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Genesis HealthCare (NYSE:GEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Genesis HealthCare in the last 12 months. Their average twelve-month price target is $2.00, suggesting that the stock has a possible upside of 27.39%. The high price target for GEN is $2.00 and the low price target for GEN is $2.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Hold | Hold | Buy | Buy |
Consensus Rating Score: | 2.33 | 2.33 | 2.50 | 2.50 |
Ratings Breakdown: | 0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s) |
Consensus Price Target: | $2.00 | $2.00 | $2.00 | $2.00 |
Price Target Upside: | 27.39% upside | 30.72% upside | 96.08% upside | 96.08% upside |
Genesis HealthCare (NYSE:GEN) Consensus Price Target History

Genesis HealthCare (NYSE:GEN) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Genesis HealthCare (NYSE:GEN) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
(Data available from 1/1/2013 forward)
Genesis HealthCare (NYSE GEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 57.59%
Institutional Ownership Percentage: 18.93%
Genesis HealthCare (NYSE GEN) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
6/14/2017 | Joanne Susan Reifsnyder | EVP | Sell | 5,269 | $1.73 | $9,115.37 | | |
6/14/2017 | Michael Scott Sherman | SVP | Sell | 3,903 | $1.73 | $6,752.19 | | |
6/14/2017 | Paul David Bach | COO | Sell | 6,100 | $1.73 | $10,553.00 | | |
6/14/2017 | Stephen Scott Young | VP | Sell | 3,799 | $1.73 | $6,572.27 | | |
6/14/2017 | Thomas Divittorio | CFO | Sell | 6,341 | $1.73 | $10,969.93 | | |
6/7/2017 | Daniel Allen Hirschfeld | COO | Sell | 2,895 | $1.61 | $4,660.95 | | |
6/7/2017 | Joanne Susan Reifsnyder | EVP | Sell | 2,383 | $1.61 | $3,836.63 | | |
6/7/2017 | Michael Scott Sherman | SVP | Sell | 1,824 | $1.61 | $2,936.64 | | |
6/7/2017 | Stephen Scott Young | VP | Sell | 1,541 | $1.61 | $2,481.01 | | |
6/7/2017 | Thomas Divittorio | CFO | Sell | 2,900 | $1.61 | $4,669.00 | | |
8/29/2016 | Stephen Scott Young | VP | Sell | 10,000 | $2.38 | $23,800.00 | | |
6/8/2016 | Daniel Allen Hirschfeld | COO | Sell | 3,009 | $1.72 | $5,175.48 | 488,220 | |
6/8/2016 | George V Hager Jr | CEO | Sell | 6,031 | $1.72 | $10,373.32 | 1,542,780 | |
6/8/2016 | Joanne Susan Reifsnyder | EVP | Sell | 2,207 | $1.72 | $3,796.04 | 286,468 | |
6/8/2016 | Michael Scott Sherman | SVP | Sell | 1,919 | $1.72 | $3,300.68 | 423,220 | |
6/8/2016 | Stephen Scott Young | VP | Sell | 1,621 | $1.72 | $2,788.12 | 172,495 | |
6/8/2016 | Thomas Divittorio | CFO | Sell | 3,051 | $1.72 | $5,247.72 | 509,220 | |
11/12/2015 | James V Mckeon | Director | Buy | 10,000 | $4.15 | $41,500.00 | 29,802 | |
11/11/2015 | Thomas Divittorio | CFO | Buy | 20,000 | $4.34 | $86,800.00 | 387,220 | |
11/14/2013 | Boyd Hendrickson | CEO | Sell | 48,774 | $5.02 | $244,845.48 | 265,430 | |
8/6/2013 | Boyd W Hendrickson | CEO | Sell | 4,983 | $6.03 | $30,047.49 | | |
8/5/2013 | Boyd W Hendrickson | CEO | Sell | 24,671 | $6.49 | $160,114.79 | | |
8/2/2013 | Boyd W Hendrickson | CEO | Sell | 45,346 | $6.58 | $298,376.68 | | |
7/2/2013 | Boyd W Hendrickson | CEO | Sell | 29,988 | $6.46 | $193,722.48 | | |
7/1/2013 | Boyd W Hendrickson | CEO | Sell | 28,112 | $6.61 | $185,820.32 | | |
11/1/2012 | Boyd W Hendrickson | CEO | Sell | 1,567 | $8.00 | $12,536.00 | | |
(Data available from 1/1/2013 forward)
Genesis HealthCare (NYSE GEN) News Headlines
Source: |
|
Date | Headline |
---|
 | -$0.31 EPS Expected for Genesis HealthCare (GEN) This Quarter www.americanbankingnews.com - April 20 at 11:28 AM |
 | Genesis HealthCare (GEN) Cut to Strong Sell at ValuEngine www.americanbankingnews.com - April 18 at 4:44 PM |
 | Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018 finance.yahoo.com - April 17 at 8:47 AM |
 | Genesis selling off 2 dozen skilled nursing facilities in Texas finance.yahoo.com - April 12 at 5:23 PM |
 | Centers Health Care Hires Heidi Hendrix, RN, As New Chief Nursing Officer www.bizjournals.com - April 12 at 8:59 AM |
 | Genesis Healthcare to divest 23 nursing facilities seekingalpha.com - April 12 at 8:59 AM |
 | Can Genomed Spólka Akcyjna (WSE:GEN) Improve Your Portfolio Returns? finance.yahoo.com - April 12 at 8:59 AM |
 | Genesis Energy Limited (NZE:GNE): Time For A Financial Health Check finance.yahoo.com - April 11 at 8:46 AM |
 | Passing of Genmab A/S’ Annual General Meeting finance.yahoo.com - April 10 at 5:19 PM |
 | Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab finance.yahoo.com - April 10 at 5:19 PM |
 | Should You Expect Genomed Spólka Akcyjna (WSE:GEN) To Continue Delivering An ROE Of 29.39%? finance.yahoo.com - April 4 at 4:02 PM |
 | Capital Increase in Genmab as a Result of Employee Warrant Exercise finance.yahoo.com - April 3 at 5:22 PM |
 | ValuEngine Downgrades Genesis Healthcare (GEN) to Hold www.americanbankingnews.com - April 3 at 2:58 PM |
 | Quorum Health (QHC) Names Terry Allison Rappuhn as New Chair; William M. Gracey Resigns www.streetinsider.com - March 26 at 8:36 AM |
 | Quorum Health (QHC) Names Terry Allison Rappuhn as New Chair; William M. Gracey Resigns - StreetInsider.com www.streetinsider.com - March 24 at 9:01 AM |
![Genesis Healthcare riding nursing-home turbulence [Philly.com] Genesis Healthcare riding nursing-home turbulence [Philly.com]](/images/news-sites/bloomberg.jpg) | Genesis Healthcare riding nursing-home turbulence [Philly.com] www.bloomberg.com - March 22 at 5:25 PM |
 | Genesis Rehab Services Achieves “World Class” Net Promoter Score finance.yahoo.com - March 22 at 5:25 PM |
 | Genesis Healthcare (GEN) & Its Competitors Head-To-Head Survey www.americanbankingnews.com - March 22 at 1:38 PM |
 | Genesis Healthcare (GEN) Rating Reiterated by Stephens www.americanbankingnews.com - March 19 at 9:30 PM |
 | Should You Be Tempted To Buy Genomed Spólka Akcyjna (WSE:GEN) Because Of Its PE Ratio? finance.yahoo.com - March 19 at 5:08 PM |
 | Genesis Healthcare, Inc. (GEN) PT Raised to $2 at Stephens - StreetInsider.com www.streetinsider.com - March 19 at 8:36 AM |
 | Canon Medical Systems’ Aquilion ONE / GENESIS Edition Delivers Full Suite of Acute Stroke Solutions www.bizjournals.com - March 18 at 8:31 AM |
 | Edited Transcript of GEN earnings conference call or presentation 16-Mar-18 12:30pm GMT finance.yahoo.com - March 17 at 8:42 AM |
 | Genesis Healthcare (GEN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow seekingalpha.com - March 16 at 6:16 PM |
 | Genesis Healthcare reports 4Q loss finance.yahoo.com - March 16 at 8:34 AM |
 | Genesis HealthCare Reports Fourth Quarter and Fiscal Year End 2017 Results finance.yahoo.com - March 16 at 8:34 AM |
 | An Intrinsic Calculation For Genesis Healthcare Inc (NYSE:GEN) Shows It’s 38% Undervalued finance.yahoo.com - March 13 at 7:07 PM |
 | Genesis Healthcare (GEN) Set to Announce Quarterly Earnings on Monday www.americanbankingnews.com - March 12 at 2:56 AM |
 | Quotidian Technical Highlights on Selected Long-Term Care Facilities Stocks -- Brookdale Senior Living, Envision ... - PR Newswire (press release) www.prnewswire.com - March 10 at 8:35 AM |
 | Genesis HealthCare Regains Compliance With NYSE Continued Listing Standard - GlobeNewswire (press release) globenewswire.com - March 3 at 6:12 PM |
 | At $1.17, Is Genesis Healthcare Inc (NYSE:GEN) A Buy? finance.yahoo.com - March 2 at 5:54 PM |
 | Genesis HealthCare Regains Compliance With NYSE Continued Listing Standard finance.yahoo.com - March 1 at 5:40 PM |
 | Understanding Genesis Healthcare’s Financial Performance finance.yahoo.com - February 27 at 5:45 PM |
 | Key Risks Facing Genesis Healthcare in 2018 finance.yahoo.com - February 27 at 5:45 PM |
 | Exploring Genesis Healthcare’s Business Segments finance.yahoo.com - February 27 at 5:45 PM |
 | Genesis Healthcare, Pioneer of Genetic Test Service, Raises 1.65 Billion Yen Newly - PR Newswire (press release) www.prnewswire.com - February 27 at 8:34 AM |
![[$$] Genesis Healthcare Refinances Debt Load Amid Restructuring [$$] Genesis Healthcare Refinances Debt Load Amid Restructuring](/images/news-sites/YahooFinance.jpg) | [$$] Genesis Healthcare Refinances Debt Load Amid Restructuring finance.yahoo.com - February 23 at 5:44 PM |
 | Shares in U.S. senior housing chains Genesis, Brookdale slide www.reuters.com - February 23 at 8:37 AM |
 | Welltower Reports Fourth Quarter 2017 Results www.bizjournals.com - February 22 at 5:28 PM |
 | Genesis Healthcare gets some debt relief finance.yahoo.com - February 22 at 5:28 PM |
 | Asset Sales Continue Holding Down Welltower Inc's Results finance.yahoo.com - February 22 at 5:28 PM |
 | With A -32.62% Earnings Drop Lately, Did Genesis Healthcare Inc (NYSE:GEN) Underperform Its Industry? finance.yahoo.com - February 20 at 5:35 PM |
 | BRIEF-Genesis Healthcare To Extend "Lock-Up" Period Of Shares Until July 31 www.reuters.com - February 16 at 5:10 PM |
 | Genesis Healthcare (GEN) Scheduled to Post Quarterly Earnings on Tuesday www.americanbankingnews.com - February 13 at 2:56 AM |
 | Blockchain Technology May Change the World, But What Are the Risks? www.thestreet.com - February 10 at 9:38 AM |
 | Nursing home giant Genesis eyes approval for $26M Dracut facility finance.yahoo.com - February 9 at 9:46 AM |
 | Genesis HealthCare to Present at the 36th Annual J. P. Morgan Healthcare Conference on January 11, 2018 finance.yahoo.com - January 3 at 5:01 PM |
 | ETFs with exposure to Genesis Healthcare, Inc. : January 1, 2018 finance.yahoo.com - January 1 at 4:53 PM |
 | ETFs with exposure to Genesis Healthcare, Inc. : December 19, 2017 finance.yahoo.com - December 19 at 4:57 PM |
 | Genesis Healthcare, Inc. :GEN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017 finance.yahoo.com - December 18 at 4:55 PM |
Genesis HealthCare (NYSE:GEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Genesis HealthCare (NYSE:GEN) Income Statement, Balance Sheet and Cash Flow Statement
Genesis HealthCare (NYSE GEN) Stock Chart for Friday, April, 20, 2018
Loading chart…